S&P 500   4,357.08 (-1.94%)
DOW   34,347.50 (-1.50%)
QQQ   361.23 (-2.46%)
AAPL   142.72 (-1.82%)
MSFT   285.99 (-2.78%)
FB   340.67 (-3.65%)
GOOGL   2,723.60 (-3.47%)
TSLA   781.46 (-1.25%)
AMZN   3,315.00 (-2.67%)
NVDA   208.58 (-3.70%)
BABA   150.55 (+0.25%)
NIO   35.36 (-3.83%)
CGC   14.29 (-2.86%)
GE   105.13 (-0.21%)
MU   73.69 (-1.98%)
AMD   103.16 (-4.62%)
T   27.25 (-0.55%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.60 (-1.49%)
PFE   42.85 (-1.65%)
BA   219.55 (-2.06%)
AMC   37.92 (-3.51%)
S&P 500   4,357.08 (-1.94%)
DOW   34,347.50 (-1.50%)
QQQ   361.23 (-2.46%)
AAPL   142.72 (-1.82%)
MSFT   285.99 (-2.78%)
FB   340.67 (-3.65%)
GOOGL   2,723.60 (-3.47%)
TSLA   781.46 (-1.25%)
AMZN   3,315.00 (-2.67%)
NVDA   208.58 (-3.70%)
BABA   150.55 (+0.25%)
NIO   35.36 (-3.83%)
CGC   14.29 (-2.86%)
GE   105.13 (-0.21%)
MU   73.69 (-1.98%)
AMD   103.16 (-4.62%)
T   27.25 (-0.55%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.60 (-1.49%)
PFE   42.85 (-1.65%)
BA   219.55 (-2.06%)
AMC   37.92 (-3.51%)
S&P 500   4,357.08 (-1.94%)
DOW   34,347.50 (-1.50%)
QQQ   361.23 (-2.46%)
AAPL   142.72 (-1.82%)
MSFT   285.99 (-2.78%)
FB   340.67 (-3.65%)
GOOGL   2,723.60 (-3.47%)
TSLA   781.46 (-1.25%)
AMZN   3,315.00 (-2.67%)
NVDA   208.58 (-3.70%)
BABA   150.55 (+0.25%)
NIO   35.36 (-3.83%)
CGC   14.29 (-2.86%)
GE   105.13 (-0.21%)
MU   73.69 (-1.98%)
AMD   103.16 (-4.62%)
T   27.25 (-0.55%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.60 (-1.49%)
PFE   42.85 (-1.65%)
BA   219.55 (-2.06%)
AMC   37.92 (-3.51%)
S&P 500   4,357.08 (-1.94%)
DOW   34,347.50 (-1.50%)
QQQ   361.23 (-2.46%)
AAPL   142.72 (-1.82%)
MSFT   285.99 (-2.78%)
FB   340.67 (-3.65%)
GOOGL   2,723.60 (-3.47%)
TSLA   781.46 (-1.25%)
AMZN   3,315.00 (-2.67%)
NVDA   208.58 (-3.70%)
BABA   150.55 (+0.25%)
NIO   35.36 (-3.83%)
CGC   14.29 (-2.86%)
GE   105.13 (-0.21%)
MU   73.69 (-1.98%)
AMD   103.16 (-4.62%)
T   27.25 (-0.55%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.60 (-1.49%)
PFE   42.85 (-1.65%)
BA   219.55 (-2.06%)
AMC   37.92 (-3.51%)
NASDAQ:RDHL

RedHill Biopharma Stock Forecast, Price & News

$4.93
-0.21 (-4.09 %)
(As of 09/28/2021 12:16 PM ET)
Add
Compare
Today's Range
$4.84
$5.20
50-Day Range
$4.55
$10.36
52-Week Range
$4.48
$11.52
Volume14,612 shs
Average Volume564,898 shs
Market Capitalization$230.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
30 days | 90 days | 365 days | Advanced Chart
Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.


RedHill Biopharma logo

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDHL
Phone
N/A
Employees
182
Year Founded
N/A

Sales & Book Value

Annual Sales
$64.36 million
Book Value
$0.30 per share

Profitability

Net Income
$-76,170,000.00
Net Margins
-112.40%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$230.07 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

776th out of 1,353 stocks

Pharmaceutical Preparations Industry

379th out of 666 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












RedHill Biopharma (NASDAQ:RDHL) Frequently Asked Questions

Is RedHill Biopharma a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RedHill Biopharma in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RedHill Biopharma stock.
View analyst ratings for RedHill Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than RedHill Biopharma?

Wall Street analysts have given RedHill Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but RedHill Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting RedHill Biopharma?

RedHill Biopharma saw a increase in short interest in August. As of August 13th, there was short interest totaling 2,030,000 shares, an increase of 21.6% from the July 29th total of 1,670,000 shares. Based on an average daily trading volume, of 303,700 shares, the short-interest ratio is currently 6.7 days. Currently, 4.4% of the shares of the company are sold short.
View RedHill Biopharma's Short Interest
.

When is RedHill Biopharma's next earnings date?

RedHill Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for RedHill Biopharma
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its earnings results on Wednesday, August, 25th. The biotechnology company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.20. The biotechnology company earned $21.50 million during the quarter, compared to analysts' expectations of $23.15 million. RedHill Biopharma had a negative net margin of 112.40% and a negative trailing twelve-month return on equity of 303.29%.
View RedHill Biopharma's earnings history
.

How has RedHill Biopharma's stock price been impacted by COVID-19 (Coronavirus)?

RedHill Biopharma's stock was trading at $3.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RDHL stock has increased by 22.3% and is now trading at $4.88.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RDHL?

6 equities research analysts have issued 1-year price objectives for RedHill Biopharma's shares. Their forecasts range from $12.00 to $22.00. On average, they expect RedHill Biopharma's stock price to reach $18.17 in the next year. This suggests a possible upside of 272.3% from the stock's current price.
View analysts' price targets for RedHill Biopharma
or view top-rated stocks among Wall Street analysts.

Who are RedHill Biopharma's key executives?

RedHill Biopharma's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 55, Pay $555.97k)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 52, Pay $418.05k)
  • Mr. Gilead Raday, Chief Operating Officer (Age 46, Pay $388.25k)
  • Mr. Adi Frish, Chief Corp. & Bus. Devel. Officer (Age 51, Pay $407.21k)
  • Mr. Rick D. Scruggs, Chief Commercial Officer, Head of US Operations & Director (Age 61, Pay $577.99k)
  • Mr. Ben Martie, VP, Legal Affairs
  • Ms. Valerie Graceffa, VP of Sales
  • Mr. Rob Jackson, Sr. VP of Sales & Marketing
  • Ms. Michelle Snelling, VP of HR
  • Dr. Reza Fathi, Sr. VP of R&D (Age 66)

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Disciplined Growth Investors Inc. MN (4.26%), Ibex Investors LLC (2.09%), ARK Investment Management LLC (1.70%), BlackRock Inc. (0.62%), Wells Fargo & Company MN (0.56%) and Citadel Advisors LLC (0.00%).

Which institutional investors are selling RedHill Biopharma stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Ibex Investors LLC, Creative Planning, Susquehanna International Group LLP, BlackRock Inc., Bank of America Corp DE, Goldman Sachs Group Inc., and Cutler Group LP.

Which institutional investors are buying RedHill Biopharma stock?

RDHL stock was bought by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, GSA Capital Partners LLP, Wells Fargo & Company MN, Woodward Diversified Capital LLC, Morgan Stanley, Morgan Stanley, Renaissance Technologies LLC, and State Street Corp.

How do I buy shares of RedHill Biopharma?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $4.88.

How much money does RedHill Biopharma make?

RedHill Biopharma has a market capitalization of $227.73 million and generates $64.36 million in revenue each year. The biotechnology company earns $-76,170,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis.

How many employees does RedHill Biopharma have?

RedHill Biopharma employs 182 workers across the globe.

What is RedHill Biopharma's official website?

The official website for RedHill Biopharma is www.redhillbio.com.

Where are RedHill Biopharma's headquarters?

RedHill Biopharma is headquartered at 21 Ha'arba'a Street, Tel Aviv L3, 64739.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.